We are committed to addressing some of the most challenging and impactful conditions affecting individuals with neurological disorders, as well as their caring families.
Alzheimer’s Disease (AD) is a progressive and irreversible brain disorder that slowly erodes memory, cognitive abilities, and essential functions for independent living. It is the most common form of dementia and poses significant emotional, physical, and financial challenges for individuals and their families.
Parkinson’s Disease (PD) is a progressive neurological disorder that affects movement, balance, and coordination. It is primarily caused by the degeneration of dopamine-producing neurons in the brain, leading to motor symptoms such as tremors, stiffness, and slowed movement.
Rett Syndrome (RS) is a rare neurological disorder that primarily affects girls, causing severe cognitive, motor, and communication impairments. It is typically diagnosed in early childhood and is often marked by a loss of previously acquired skills.
Fragile X Syndrome (FXS) is the most common inherited cause of intellectual disability and developmental delays. It is a genetic condition that affects learning, behavior, and social interactions, often presenting alongside physical and emotional challenges.
Infantile spasms are a rare and severe form of epilepsy that typically begin in infancy. These spasms are characterized by sudden, jerking movements and are often accompanied by developmental delays and abnormal brain wave patterns, requiring immediate medical attention.
Angelman Syndrome is a rare genetic disorder that affects the nervous system, leading to developmental delays, movement and balance issues, minimal to no speech, and frequent seizures. Despite these challenges, individuals with Angelman Syndrome often exhibit a happy demeanor, with frequent smiling and laughter.
This undisclosed rare disease represents a unique and complex medical challenge, requiring advanced research and tailored therapeutic solutions to improve outcomes for affected individuals.
Schizophrenia is a chronic mental health condition that affects thought processes, perceptions, and behavior, often causing delusions, hallucinations, and difficulties with social interaction.
Frontotemporal Dementia (FTD) is a group of neurodegenerative disorders that primarily affect the frontal and temporal lobes of the brain, leading to changes in behavior, personality, language, and movement. It is a major cause of dementia in individuals under the age of 65.
Alzheimer’s Disease (AD) is a progressive and irreversible brain disorder that slowly erodes memory, cognitive abilities, and essential functions for independent living. It is the most common form of dementia and poses significant emotional, physical, and financial challenges for individuals and their families.
Depression is a common yet serious mental health condition that affects how a person feels, thinks, and handles daily activities. It goes beyond temporary sadness, often disrupting an individual’s ability to function and diminishing their overall quality of life.
A stroke is a medical emergency that occurs when blood flow to the brain is interrupted, either due to a blocked artery (ischemic stroke) or a ruptured blood vessel (hemorrhagic stroke). This disruption leads to brain cell death, resulting in physical, cognitive, and emotional impairments.
Neurodegenerative diseases are a group of progressive disorders characterized by the loss of structure or function of neurons, leading to cognitive, motor, and behavioral impairments.
Visceral pain originates from the internal organs, often described as deep, aching, or cramping, and is commonly associated with conditions like irritable bowel syndrome or endometriosis.
Acute and neuropathic pain are distinct but debilitating types of pain: acute pain arises suddenly due to injury or illness, while neuropathic pain results from nerve damage or dysfunction, often persisting long-term.
Our SIGMACEPTOR™ Discovery Platform consists of differentiated clinical-stage CNS assets targeting significant and growing markets. Anavex Life Sciences has patent protection to 2030-2039. World-wide rights for all listed product candidates.
